Company / R&D Expense
TG Therapeutics, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$160.2M
FY2025
5-year range
$76.2M / $222.6M
FY2021-FY2025
Trend
+69.9%
vs FY2024
Sector context
#101 of 210
Health Care
What the data says
At $160M, TG Therapeutics, Inc.'s r&d expense ranks #101 of 210 in the Health Care sector. R&D Expense has fluctuated over the past 10 years, ranging from $69M in FY2016 to $223M in FY2021.
Based on SEC 10-K filings.
$160M in FY2025 with a 5-year CAGR of -0.7%.
Improved from $76M to $160M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +8.5%
- 5-Year CAGR
- -0.7%
- 10-Year CAGR
- -
Sector benchmark
#101 of 210 in Health CareTop 48% of 210This company $160.2M Sector average $644.1M
▼
-75.1% below sector average
Key checks
Key Insights
- 5-year CAGR of -0.7%, indicating a declining trend.
- In FY2025, r&d expense increased 69.9% year-over-year.
- Ranks #101 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 1.05 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $160.2M | +69.9% |
| FY2024 | $94.3M | +23.8% |
| FY2023 | $76.2M | -39.2% |
| FY2022 | $125.4M | -43.7% |
| FY2021 | $222.6M | +34.2% |
| FY2020 | $165.9M | +61.8% |
| FY2019 | $102.5M | -35.7% |
| FY2018 | $159.4M | +55.5% |
| FY2017 | $102.5M | +48.1% |
| FY2016 | $69.2M | +45.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026